Latest Releases
Sens. Smith, Stabenow, and Rep. Maloney Lead Colleagues in Introducing Bicameral Package of Legislation to Target Abusive Pharmaceutical Business Practices
Washington, D.C. [04.07.22]—Today, Sens. Tins Smith (D-MN), Debbie Stabenow (D-MI), and Rep. Carolyn B. Maloney (D-NY-12), led colleagues—including Rep. Peter Welch and Rep. Jan Schakowsky—in introducing a package of legislation targeting business practices pharmaceutical companies use to suppress competition, maintain market monopolies, and keep drug prices high. The legislative reforms follow the Oversight Committee’s three-year investigation into pharmaceutical pricing and business practices that exposed pharmaceutical company practices to suppress competition from lower-priced generics and biosimilars and make drug prices unaffordable for many Americans. “There is no good reason Americans should be paying more than any country in the world for their prescription drugs.” said Sen. Smith. “This bill would prevent large pharmaceutical companies from using anti-competitive tactics that keep prices high for families struggling to pay for life saving drugs. I will keep pushing to make sure this commonsense legislation gets across the finish line.” “The House Oversight Committee and I have partnered for years to expose how the American people are being ripped off by drug companies who use taxpayer-funded research to develop lifesaving prescription drugs. We have seen how these drug companies then turn around and charge exorbitant prices for these drugs when people need them the most, without ever having to disclose what they actually spend on research and development. Today, Chairwoman Maloney, Senator Smith and I are introducing new bills to finally put an end to these practices,” said Sen. Stabenow. “In 2022, no one should be making the hard choice of paying for needed medications
Sens. Smith, Stabenow, and Rep. Maloney Lead Colleagues in Introducing Bicameral Package of Legislation to Target Abusive Pharmaceutical Business Practices
Washington, D.C. [04.07.22]—Today, Sens. Tins Smith (D-MN), Debbie Stabenow (D-MI), and Rep. Carolyn B. Maloney (D-NY-12), led colleagues—including Rep. Peter Welch and Rep. Jan Schakowsky—in introducing a package of legislation targeting business practices pharmaceutical companies use to suppress competition, maintain market monopolies, and keep drug prices high. The legislative reforms follow the Oversight Committee’s three-year investigation into pharmaceutical pricing and business practices that exposed pharmaceutical company practices to suppress competition from lower-priced generics and biosimilars and make drug prices unaffordable for many Americans. “There is no good reason Americans should be paying more than any country in the world for their prescription drugs.” said Sen. Smith. “This bill would prevent large pharmaceutical companies from using anti-competitive tactics that keep prices high for families struggling to pay for life saving drugs. I will keep pushing to make sure this commonsense legislation gets across the finish line.” “The House Oversight Committee and I have partnered for years to expose how the American people are being ripped off by drug companies who use taxpayer-funded research to develop lifesaving prescription drugs. We have seen how these drug companies then turn around and charge exorbitant prices for these drugs when people need them the most, without ever having to disclose what they actually spend on research and development. Today, Chairwoman Maloney, Senator Smith and I are introducing new bills to finally put an end to these practices,” said Sen. Stabenow. “In 2022, no one should be making the hard choice of paying for needed medications
Klobuchar, Smith Urge Department of Health and Human Services (HHS) to Restore Full Federal Funding for MinnesotaCare
WASHINGTON- U.S. Senators Amy Klobuchar and Tina Smith strongly urged the Department of Health and Human Services (HHS) to restore the full amount of federal funding that has been cut from MinnesotaCare over the past year. Minnesota, New York, and HHS have recently reached an agreement about a lawsuit regarding cost-sharing reduction (CSR) payments. Under the agreement, HHS will develop a new system for providing federal funding for Basic Health Programs (BHP) like MinnesotaCare. In the letter to HHS Secretary Alex Azar and Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma, the senators called for full funding for
Klobuchar, Smith Urge Department of Health and Human Services (HHS) to Restore Full Federal Funding for MinnesotaCare
WASHINGTON- U.S. Senators Amy Klobuchar and Tina Smith strongly urged the Department of Health and Human Services (HHS) to restore the full amount of federal funding that has been cut from MinnesotaCare over the past year. Minnesota, New York, and HHS have recently reached an agreement about a lawsuit regarding cost-sharing reduction (CSR) payments. Under the agreement, HHS will develop a new system for providing federal funding for Basic Health Programs (BHP) like MinnesotaCare. In the letter to HHS Secretary Alex Azar and Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma, the senators called for full funding for
Sens. Tina Smith, Thom Tillis Lead Bipartisan Introduction of Bill to Support Health Care for “Atomic Veterans”
WASHINGTON, D.C. [05/11/18]—U.S. Senators Tina Smith and Thom Tillis (R-N.C.) have introduced a bipartisan measure to support health care benefits for “Atomic Veterans” who were exposed to harmful radiation when they cleaned up nuclear testing sites during the late 1970s. The Mark Takai Atomic Veterans Healthcare Parity Act would allow veterans who participated in the cleanup of Enewetak Atoll on the Marshall Islands to receive the same healthcare and benefits given to other servicemembers who were involved in active nuclear tests. From 1946 to 1958 the U.S. military conducted more than 40 nuclear tests in the Islands, but the
Sen. Tina Smith’s Statement on President’s Prescription Drug Address
WASHINGTON, D.C. [05/11/18]—Today, U.S. Senator Tina Smith released the following statement after President Trump delivered an address focused on prescription drug prices. “When I meet with everyone from farmers, to small business owners, to families—they tell me about the high cost of health care, including the high cost of prescription drugs. I’ve heard from a young mother whose cancer medications cost $20,000 a month, and from seniors in Minnesota who are forced to choose between food and medicine. This is just wrong,” said Sen. Smith. “Today, the President said we need to bring down prescription drug prices and address ‘pay-for-delay’—the Big Pharma
English